血浆代谢物与骨质疏松症之间的因果关系：一项双向孟德尔随机研究

doi:10.24920/004356

Abstract

Objective To investigate the causal relationships between plasma metabolites and osteoporosis via Mendelian randomization (MR) analysis.
Methods Bidirectional MR was used to analyze pooled data from different genome-wide association studies (GWAS) to investigate the causal relationships between plasma metabolites and osteoporosis. The causal effect of plasma metabolites on osteoporosis was estimated using the inverse variance weighted method, intersections of statistically significant metabolites obtained from different sources of osteoporosis-related GWAS aggregated data was determined, and then sensitivity analysis was performed on these metabolites. Heterogeneity between single nucleotide polymorphisms was evaluated by Cochran’s Q test. Horizontal pleiotropy was assessed through the application of the MR-Egger intercept method and the MR-PRESSO method. The causal effect of osteoporosis on plasma metabolites was also evaluated using the inverse variance weighted method. Additionally, pathway analysis was conducted to identify potential metabolic pathways involved in the regulation of osteoporosis.
Results After primary analysis and a series of sensitivity analyses, 77 and 61 plasma metabolites were identified as having a causal relationship with osteoporosis from the GWAS data in the GCST90038656 and GCST90044600 datasets , respectively. Five common metabolites were identified via intersection. X-13684 levels (GCST90038656: OR = 0.999, 95% CI, 0.998-1.000, P = 0.004; GCST90044600 (OR = 0.834, 95% CI, 0.700-0.993, P = 0.042), and the glucose-to-maltose ratio (GCST90038656: OR = 0.998, 95% CI, 0.997-1.000, P = 0.025; GCST90044600: OR = 0.752, 95% CI, 0.576-0.981, P = 0.036) were negatively associated with osteoporosis, whereas glycoursodeoxycholate levels (GCST90038656: OR = 1.002, 95% CI, 1.000-1.003, P = 0.032; GCST90044600: OR = 1.331, 95% CI, 1.036-1.709, P = 0.025) and arachidoylcarnitine (C20) levels (GCST90038656: OR = 1.001, 95% CI, 1.000-1.003, P = 0.039; GCST90044600: OR = 1.237; 95% CI, 1.008-1.518, P = 0.042) were positively associated with osteoporosis. The relationship between X-11299 levels and osteoporosis showed contradictory results (GCST90038656: OR= 0.998, 95% CI, 0.997-1.000, P = 0.026; GCST90044600: OR = 1.402, 95% CI, 1.071-1.834, P = 0.014). Pathway analysis indicated that glycine, serine, and threonine metabolism, valine, leucine, and isoleucine biosynthesis, galactose metabolism, arginine biosynthesis, and starch and sucrose metabolism pathways were participated in the development of osteoporosis.
Conclusion We found a causal relationship between plasma metabolites and osteoporosis. These results offer novel perspectives that have implications for targeted interventions focused on metabolites in the management of osteoporosis.

Key words: osteoporosis, plasma metabolites, mendelian randomization, bidirectional analysis

Funding:

Hao Lv, Ge Zhang, Zhi-Mu Hu, Qing-Song Chu, Jiu-Xiang Wang, Ting Jiang. Dissecting Causal Relationships Between Plasma Metabolites and Osteoporosis: A Bidirectional Mendelian Randomization Study[J/OL].Chinese Medical Sciences Journal, .DOI:10.24920/004356.[Epub ahead of print].

References

[1] Gopinath V.Osteoporosis. Med Clin N Am 2023; 107(2):213-25. doi: 10.1016/j.mcna.2022.10.013.
[2] Trajanoska K, Rivadeneira F.The genetic architecture of osteoporosis and fracture risk. Bone 2019; 126:2-10. doi: 10.1016/j.bone.2019.04.005.
[3] Guijas C, Montenegro-Burke JR, Warth B, et al.Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol 2018; ,36(4):316-20. doi: 10.1038/nbt.4101.
[4] Fan J, Jahed V, Klavins K.Metabolomics in bone research. Metabolites 2021; 11(7):1-17. doi: 10.3390/metabo11070434.
[5] Wang J, Wang Y, Zeng Y, et al.Feature selection approaches identify potential plasma metabolites in postmenopausal osteoporosis patients. Metabolomics 2022; 18(11):1-12. doi: 10.1007/s11306-022-01937-0.
[6] He J, Gai J.Genome-wide association studies (GWAS). Methods Mol Biol 2023; 2638:123-46. doi: 10.1007/978-1-0716-3024-2_9.
[7] Birney E. Mendelian Randomization. Csh Perspect Med 2022; 12(4):1-4. doi: 10.1101/cshperspect.a041302.
[8] Bowden J, Holmes MV.Meta-analysis and Mendelian randomization: a review. Res Synth Methods 2019; 10(4):486-96. doi: 10.1002/jrsm.1346.
[9] Chen Y, Lu T, Pettersson-Kymmer U, et al.Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet 2023; 55(1):44-53. doi: 10.1038/s41588-022-01270-1.
[10] Bowden J, Davey SG, Burgess S.Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44(2):512-25. doi: 10.1093/ije/dyv080.
[11] Pierce BL, Burgess S.Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013; 178(7):1177-84. doi: 10.1093/aje/kwt084.
[12] Broadbent JR, Foley CN, Grant AJ, et al.MendelianRandomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data. Wellcome Open Res 2020; 5(252):1-21. doi: 10.12688/wellcomeopenres.16374.2.
[13] Verbanck M, Chen CY, Neale B, et al.Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018; 50(5):693-8. doi: 10.1038/s41588-018-0099-7.
[14] Liu H, Gu R, Zhu Y, et al.D-mannose attenuates bone loss in mice via Treg cell proliferation and gut microbiota-dependent anti-inflammatory effects. Ther Adv Chronic Dis 2020; 11:1-17. doi: 10.1177/2040622320912661.
[15] Yang T, Liu S, Ma H, et al.Carnitine functions as an enhancer of NRF2 to inhibit osteoclastogenesis via regulating macrophage polarization in osteoporosis. Free Radical Bio Med 2024; 213:174-89. doi: 10.1016/j.freeradbiomed.2024.01.017.
[16] Nishihara S, Ikeda M, Ozawa H, et al.Role of cAMP in phenotypic changes of osteoblasts. Biochem Bioph Res Co 2018; 495(1):941-6. doi: 10.1016/j.bbrc.2017.11.125.
[17] Wang Y, Deng P, Liu Y, et al.Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nat Commun 2020; 11(1):1-14. doi: 10.1038/s41467-020-19360-1.
[18] Shen L, Yu Y, Karner CM.SLC38A2 provides proline and alanine to regulate postnatal bone mass accrual in mice. Front Physiol 2022; 13:1-14. doi: 10.3389/fphys.2022.992679.
[19] Lee S, Kim HS, Kim MJ, et al.Glutamine metabolite alpha-ketoglutarate acts as an epigenetic co-factor to interfere with osteoclast differentiation. Bone 2021; 145:1-29. doi: 10.1016/j.bone.2020.115836.
[20] Cheng C, Xing Z, Hu Q, et al.A bone-targeting near-infrared luminescence nanocarrier facilitates alpha-ketoglutarate efficacy enhancement for osteoporosis therapy. Acta Biomater 2024; 173:442-56. doi: 10.1016/j.actbio.2023.11.022.
[21] Mikkelsen RB, Arora T, Trost K, et al.Type 2 diabetes is associated with increased circulating levels of 3-hydroxydecanoate activating GPR84 and neutrophil migration. Iscience 2022; 25(12):1-28. doi: 10.1016/j.isci.2022.105683.
[22] Anaya JM, Bollag WB, Hamrick MW, et al.The role of tryptophan metabolites in musculos21186670.
[23] Cao S, Li Y, Song R, et al.L-arginine metabolism inhibits arthritis and inflammatory bone loss. Ann Rheum Dis 2024; 83(1):72-87. doi: 10.1136/ard-2022-223626.
[24] Shen L, Yu Y, Zhou Y, et al.SLC38A2 provides proline to fulfill unique synthetic demands arising during osteoblast differentiation and bone formation. Elife 2022;11:1-64. doi: 10.7554/eLife.76963.
[25] Tousen Y, Matsumoto Y, skeletal stem cell aging. Int J Mol Sci 2020; 21(18):1-14. doi: 10.3390/ijm.
[26] Meng KL, Jiao MZ, Shi XG, et al.A rapid approach to capture the potential bioactive compounds from Rhizoma Drynariae, utilizing disease-associated mutation in calcium sensing receptor to alter the binding affinity for agonists. J Pharmaceut Biomed 2023; (226):1-10. doi: 10.1016/j.jpba.2023.115253.
[27] Wang Q, Gao Z, Guo K, et al. Human Umbilical Cord Wharton Jelly Cells Treatment Prevents Osteoporosis Induced by D-Galactose. Int J Clin Pract2022; July:1-10. doi: 10.1155/2022/4593443.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

Dissecting Causal Relationships Between Plasma Metabolites and Osteoporosis: A Bidirectional Mendelian Randomization Study

PDF (PC)

Supplement

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Metrics

Recommended 3

[1]	Tang Hui,Zhu Xiaowei,Wu Longfei,Mo Xingbo,Deng Feiyan,Lei Shufeng. Integrative Analysis Confirmed the Association between Osteoprotegerin and Osteoporosis [J]. Chinese Medical Sciences Journal, 2019, 34(2): 147-156.
[2]	Lei Tan, Yan-hui Li, Xin Dong, Bin Zhao, Dong Zhu. Effect of 4-week Whole Body Vibration on Distal Radius Density [J]. Chinese Medical Sciences Journal, 2016, 31(2): 95-99.
[3]	Lan-wen Han, Dou-dou Ma, Xiao-jie Xu, Fang Lü, Yi Liu, Wei-bo Xia, Yan Jiang, Ou Wang, Xiao-ping Xing, Mei Li. Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women [J]. Chinese Medical Sciences Journal, 2016, 31(1): 8-16.
[4]	Zhe-yuan Huang, Bi-long Yi, and Hao-yuan Liu*. Sternal Insufficiency Fractures of Post-menopausal Women: Retrospective Analysis of 17 Cases [J]. Chinese Medical Sciences Journal, 2012, 27(2): 101-105.